Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Catherine Daniel"'
Autor:
Lauren E. Strelec, Sunita D. Nasta, Jakub Svoboda, Sarah Brooks, Prioty Islam, Chadi Nabhan, Anthony R. Mato, Catherine Daniel, Alex Ganetsky, David L. Porter, Stephen J. Schuster, Adam H. Kaye
Publikováno v:
Blood. 127:1064-1067
To the editor: Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder partly dependent on the B-cell receptor (BCR) signaling pathway. The novel BCR signal transduction inhibitor ibrutinib has emerged as an effective therapeutic
Autor:
Pavel Kiselev, Chaitra S. Ujjani, Melissa Yacur, Molly Fanning, Stephen J. Schuster, Allan-Louie Cruz, Paul M. Barr, Clive S. Zent, Spencer Henick Bachow, Anthony R. Mato, Bruce D. Cheson, Nicole Lamanna, Brian T. Hill, Alan P Skarbnik, Jeffrey J. Pu, Catherine Daniel, Danielle M. Brander, Christina Howlett, Allison M. Winter, Colleen Timlin, Krista Isaack, David F. Claxton, Jakub Svoboda, Chadi Nabhan, Kaitlin Kennard
Publikováno v:
Blood. 128:4400-4400
Introduction: Ibrutinib (Ibr), idelalisib (Ide), andvenetoclax (Ven), are all now approved for treating CLL patients in the US. However, in the absence of head-to-head comparator trials, there is limited guidance as to the optimal sequence of these t
Autor:
Anthony R. Mato, David F. Claxton, Bruce D. Cheson, Jeffrey J. Pu, Clive S. Zent, Molly Fanning, Colleen Timlin, Lauren E. Strelec, Krista Isaack, Allan-Louie Cruz, Paul M. Barr, Nicole Lamanna, David L. Porter, Catherine Daniel, Daniel J. Landsburg, Spencer Henick Bachow, Chaitra S. Ujjani, Pavel Kiselev, Melissa Yacur, Christina Howlett, Allison M. Winter, Danielle M. Brander, Kaitlin Kennard, Chadi Nabhan, Stephen J. Schuster, Brian T. Hill, Alan P Skarbnik, Sunita D. Nasta
Publikováno v:
Blood. 128:3222-3222
Introduction: Ibrutinib (Ibr) is a kinase inhibitor (KI) indicated for treating CLL. Clinical trials that led to its approval showed that its unique side effects differ from traditional chemotherapy toxicities. We previously reported (Mato et al, ASH
Publikováno v:
Blood. 118:3154-3154
Abstract 3154 Background: Iron deficiency anemia (IDA) is a common hematologic problem worldwide, potentially leading to cognitive delays, fatigue, seizures, and, when severe, high output heart failure. While IDA frequently is encountered in both the